What is SonoVascular?
SonoVascular is at the forefront of developing a clinical-stage medical device designed to treat venous and arterial blood clots. The company's proprietary catheter platform integrates therapeutic ultrasound and microbubbles, with the capability for targeted drug delivery. This advanced system aims to effectively clear clot burden while crucially preserving vessel health, addressing a critical unmet need in vascular intervention.
How much funding has SonoVascular raised?
SonoVascular has raised a total of $6M across 1 funding round:
Series A
$6M
Series A (2026): $6M with participation from Harbright Ventures
Key Investors in SonoVascular
Harbright Ventures
Harbright Ventures is an investment firm focused on fueling the growth of innovative companies that create positive impacts on people and the planet. They provide capital resources, strategic connections, and expert guidance to early-stage businesses across various sectors, including medical technology, industrial technology, clean/green technology, and B2B SaaS.
What's next for SonoVascular?
With this major enterprise-level funding, SonoVascular is poised for significant advancement. The strategic investment signals confidence in the company's technology and its potential to disrupt the treatment of thrombotic conditions. This capital will likely fuel further clinical trials, regulatory approvals, and the scaling of manufacturing capabilities, paving the way for broader market adoption and impact on patient care.
See full SonoVascular company page
